Gilead Loses Patent Fight in China for Pricey Hep C Drug
publication date: Jun 19, 2015
China withdrew one of Gilead Sciences' patents for Sovaldi, its very expensive (and very effective) treatment for hepatitis C. Gilead charges $1,000 per Solvaldi pill ($84,000 for a twelve-week regimen). China rejected the patent on the Solvaldi prodrug, which becomes the chemically active drug in the patient's stomach. Gilead, however, continues to own IP on the active substance. In a similar case two years ago with Viread, an HIV treatment, Gilead released its patent to a pool, allowing generic copies, one year after it lost a patent fight, even though it still had other active patents. More details....
Stock Symbol: (NSDQ: GILD)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.